Restart Life Expands Intellectual Property Through Trademark Licensing Agreement
Rhea-AI Summary
Restart Life Sciences Corp (CSE: HEAL, OTC: NMLSD) has secured exclusive licensing rights to four health-related trademarks under a 5-year agreement, renewable for another 5 years. The deal includes a nominal $1 licensing fee and royalty structure of 5% on gross sales up to $1,000,000, reducing to 2.5% for sales exceeding $1,000,000.
The agreement, made with a company controlled by one of Restart Life's directors, includes a previously revenue-generating health-care brand that operated on Amazon. Royalties can be paid in cash, company common shares, or a combination of both. Both parties have agreed to negotiate the purchase of the licensed trademarks at the end of the term.
The transaction is exempt from formal valuation requirements and minority shareholder approval requirements under Multilateral Instrument 61-101 Protection of Minority Security Holders in Special Transactions.
Positive
- Minimal initial investment with $1 licensing fee
- Flexible royalty payment options including cash or shares
- Access to previously successful Amazon health-care brand
- Option to purchase trademarks at end of term
Negative
- Related party transaction with director-controlled company
- Ongoing royalty obligations of 5% on sales up to $1M
- Purchase price for trademarks not predetermined
- Previous brand ceased operations due to economic conditions
Vancouver, British Columbia--(Newsfile Corp. - March 17, 2025) - Restart Life Sciences Corp. (CSE: HEAL) (FSE: HN30) (OTC Pink: NMLSD) ("Restart Life" or the "Company") is pleased to announce that it has secured the licensing rights to health-related trademarks, a strategic move that will play a role in the Company's future brand development initiatives. This agreement aligns with Restart Life's efforts to strengthen its market position and expand its product portfolio.
Restart Life has secured an exclusive license to use four trademarks for its products under a 5-year agreement, with a renewal option for another 5 years.
The license agreement, made with a company controlled by one of the Company's directors, includes a
The Company and the licensor agreed to negotiate the purchase of the licensed trade marks at the end of the term. The acquisition price will be negotiated and mutually agreed upon by both parties at the time of the acquisition.
In a further strategic move, the agreement includes a health-care-related brand which was revenue producing through sales of health-related products on Amazon. The brand was originally developed by one of Restart Life's directors, who chose to cease operations due to economic conditions during and post-covid. Restart Life expects to receive valuable business insights to assist in revitalizing and relaunching the brand, leveraging past successes to achieve future growth.
The Company remains committed to expanding its intellectual property through a variety of agreements, acquisitions, and joint ventures to enhance its market presence and drive innovation.
"We are excited to move forward with this strategic licensing agreement, which positions Restart Life to strengthen its brand portfolio and accelerate market growth," said Steve Loutskou, CEO of Restart Life. "By acquiring these trademark licensing rights at a minimal cost, we are well-positioned to expand our product offerings, build brand awareness, and explore new business opportunities in the years to come."
The license agreement has been approved by the independent directors of the Company. The transaction is exempt from the formal valuation requirements pursuant to sections 5.5(a) Fair Market Value not More Than
Restart Life looks forward to leveraging these new licensing rights to drive innovation and introduce new products that will resonate with its growing customer base.
About Restart Life Sciences Corp.
Restart Life Science Corp. is a Canadian-based life sciences company listed on the CSE. For more information about Restart Life, please visit the Company's website at www.restartlife.co.
Forward-Looking Information
This news release contains statements that constitute "forward-looking statements." Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Restart Life Science's actual results, performance or achievements, or developments in the industry to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "potential" and similar expressions, or that events or conditions "will," "would," "may," "could" or "should" occur.
The forward-looking statements in this news release include but are not limited to the statements related to the trade marks, the use of the trade marks, the license agreement, Company's position in the market and market growth.
The Company cautions investors that any forward-looking information provided by the Company is not a guarantee of future results or performance, and that actual results may differ materially from those in forward-looking information as a result of various risk factors, including, but not limited to the ability to sell Company's products, appeal of the trademarks and Company's products to consumers, regulatory environment, taxes and tariffs.
The material assumptions used to develop forward-looking information include, but not limited to general business and economic conditions, financial markets conditions, the Company's ability to fund its operations, obtain licensees and/or permits (when required), develop, market and sell its products.
Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward-looking information. Readers are cautioned that forward-looking statements contained in this press release are made as of the date of this press release. The Company disclaims any intention to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.
On behalf of the board of directors
Chief Executive Officer - Steve Loutskou
Tel: +1 (778) 819-0244
Email: hello@restartlife.co
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/244643
FAQ
What are the key terms of Restart Life Sciences (NMLSD) trademark licensing agreement?
How can Restart Life Sciences (NMLSD) pay the royalties under the new licensing agreement?
What is the potential acquisition arrangement for the NMLSD licensed trademarks?
What existing brand is included in Restart Life Sciences' (NMLSD) licensing agreement?
